CompletedNot Applicable

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

South Korea200 participantsStarted 2005-02

Plain-language summary

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Who can participate

Age range15 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Eligible patients of either sex, 15 years of age or older * Patients who are admitted to the department of hematology and oncology * Provide written informed consent Exclusion Criteria: * Patients who have hypersensitivity to β-lactam antibiotics * Female who are pregnant or breast-feeding * Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

Trial details

NCT IDNCT00167999

SponsorWyeth is now a wholly owned subsidiary of Pfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

View on ClinicalTrials.gov More Gram-Positive Bacterial Infections trials